Background Patients at increased risk for coronary artery disease and adverse prognosis
during heart failure exhibit increased levels of circulating trimethylamine N‐oxide (TMAO), a …

Background The choline‐derived metabolite trimethylamine N‐oxide (TMAO) has been
demonstrated to contribute to atherosclerosis and is associated with coronary artery disease …

Traditional cardiovascular risk factors do not underlie all incidence of cardiovascular
disease. In recent years, accumulating evidence has demonstrated that gut microbiota and …

Cardiometabolic diseases (CMDs) have been associated with changes in the composition of
the gut microbiota, with links between the host environment and microbiota identified in …

The host-microbiota co-metabolite trimethylamine N-oxide (TMAO) is linked to increased
cardiovascular risk but how its circulating levels are regulated remains unclear. We applied …

Background Recent studies show a mechanistic link between gut microbiota-dependent
formation of the atherosclerosis-and thrombosis-promoting metabolite trimethylamine N …

The human gut microbiota environment is constantly changing and some specific changes
influence the host's metabolic, immune, and neuroendocrine functions. Emerging evidence …

Objective—Gut microbiota–dependent metabolites, in particular trimethylamine N-oxide
(TMAO), have recently been reported to promote atherosclerosis and thrombosis. Here, we …

There is a growing body of clinical evidence that supports a strong association between
elevated circulating trimethylamine N-oxide (TMAO) levels with increased risk of developing …

An increasing amount of evidence reveals that the gut microbiota is involved in the
pathogenesis and progression of various cardiovascular diseases. In patients with heart …